Minireviews
Copyright ©The Author(s) 2021.
World J Clin Oncol. Mar 24, 2021; 12(3): 164-182
Published online Mar 24, 2021. doi: 10.5306/wjco.v12.i3.164
Table 6 Key phase I/II/III involving antibody drug conjugates and targeted therapies
Trial
n
Drug
ORR 1st line
ORR ≥ 2 line
mPFS ≥ 2 line
mOS 1st line
mOS ≥ 2 line
Ref.
NCT01631552 phase II108Sacituzumab govitecan33%5.512.4Schmid et al[61], 2020
NCT03310957 phase I/II51Pembrolizumab + ladiratuzumab vedoitin54%-Han et al[78], 2020
NCT029380341 phase Ib/II21US-140233%-Kim et al[82], 2019
NCT03279257 phase 1b/II40Alpelisib57%7Sharma et al[84], 2018
LOTUS phase II124Ipatasertib40%6.2Kim et al[86], 2017
NCT02978716 phase II102Trilaciclib43%20.6/17.6Tan et al[88], 2019
ASCENT phase III529Sacituzumab Govitecan35%5.612.1Bardia et al[77], 2020